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Abstract
Background: The targeting of Ca
2+ cycling has emerged as a potential therapy for the treatment of severe heart failure.
These approaches include gene therapy directed at overexpressing sarcoplasmic reticulum (SR) Ca
2+ ATPase, or ablation of
phospholamban (PLN) and associated protein phosphatase 1 (PP1) protein complexes. We previously reported that PP1b,
one of the PP1 catalytic subunits, predominantly suppresses Ca
2+ uptake in the SR among the three PP1 isoforms, thereby
contributing to Ca
2+ downregulation in failing hearts. In the present study, we investigated whether heart-failure-inducible
PP1b-inhibition by adeno-associated viral-9 (AAV9) vector mediated gene therapy is beneficial for preventing disease
progression in genetic cardiomyopathic mice.
Methods: We created an adeno-associated virus 9 (AAV9) vector encoding PP1b short-hairpin RNA (shRNA) or negative
control (NC) shRNA. A heart failure inducible gene expression system was employed using the B-type natriuretic protein
(BNP) promoter conjugated to emerald-green fluorescence protein (EmGFP) and the shRNA sequence. AAV9 vectors (AAV9-
BNP-EmGFP-PP1bshRNA and AAV9-BNP-EmGFP-NCshRNA) were injected into the tail vein (2610
11 GC/mouse) of muscle
LIM protein deficient mice (MLPKO), followed by serial analysis of echocardiography, hemodynamic measurement,
biochemical and histological analysis at 3 months.
Results: In the MLPKO mice, BNP promoter activity was shown to be increased by detecting both EmGFP expression and the
induced reduction of PP1b by 25% in the myocardium. Inducible PP1bshRNA delivery preferentially ameliorated left
ventricular diastolic function and mitigated adverse ventricular remodeling. PLN phosphorylation was significantly
augmented in the AAV9-BNP-EmGFP-PP1bshRNA injected hearts compared with the AAV9-BNP-EmGFP-NCshRNA group.
Furthermore, BNP production was reduced, and cardiac interstitial fibrosis was abrogated at 3 months.
Conclusion: Heart failure-inducible molecular targeting of PP1b has potential as a novel therapeutic strategy for heart
failure.
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Introduction
Heart failure is a leading cause of morbidity and mortality in
developed countries and afflicts more than 55 million people in the
United States [1]. Patients with chronic heart failure manifest a
progressive form of cardiac dysfunction that is characterized by
either reduced left systolic and diastolic ventricular function, or
both sides, with ventricular remodeling, arrhythmia, and intra-
cardiac conduction disturbances [2]. Although advances in
pharmacological and non-pharmacological therapies, including
renin-angiotensin-aldosterone system inhibitors, b-adrenergic re-
ceptor blockers and cardiac resynchronization therapy devices,
have significantly contributed to improvements in morbidity and
mortality over the last decade [1], the current treatments still
remain suboptimal. Particularly in elderly patients, heart failure
not only is associated with systolic dysfunction, but also diastolic
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number of elder patients with heart failure is predicted to result in
higher health costs due to the necessity of repeated admission of
the patients [3]. Therefore, a new therapeutic strategy targeting
diastolic cardiac function is needed to help address this situation.
The failing myocardium is characterized by a reduced
intracellular Ca
2+ cycling capacity, phosphorylation imbalances,
and altered expression patterns of key proteins in the subcellular
microdomains of failing cardiomyocytes [4,5]. These include
hyperphosphorylated ryanodine receptor (RyR), reduced expres-
sion of sarcoendoplasmic reticulum Ca
2+ ATPase (SERCA2a), and
hypophosphorylated phospholamban (PLN) in the sarcoplasmic
reticulum (SR), resulting in defective intracellular Ca
2+ cycling and
progressive systolic and diastolic dysfunction. Correcting such
inefficient Ca
2+ handling by overexpressing the SERCA2a gene
[6,7] or perturbing its endogenous inhibitor, PLN [8,9,10],
successfully restored cardiac function and ameliorated heart
failure progression in a variety of experimental animal models,
clearly demonstrating that SERCA/PLN is a promising thera-
peutic target. Indeed, adeno-associated virus (AAV) vector
mediated SERCA2a gene therapy has been formally started in
clinical trials with patients with severe heart failure and showed
initial promising results without major complications [11,12].
It is also postulated that overactivation of protein phosphatase 1
(PP1) is directly associated with inefficient Ca
2+ cycling by
inducing a decreased phosphorylation of PLN in the sarcoplasmic
reticulum (SR) of failing hearts [13]. There are lines of evidences
showing that PP1 inhibition is an alternative molecular approach
for the treatment of heart failure by upregulating intracellular
Ca
2+ cycling [14,15,16]. Indeed, we and others have been shown
that gene transfer of endogenous PP1 inhibitors, such as
constitutive active inhibitor-1 (INH-1c) or inhibitor-2 (INH-2)
significantly improved cardiac function and extended survival time
in animal models of heart failure [14,15,16].
However, there are several concerns regarding clinical applica-
tions of the gene therapy approach, including immune response
against the therapeutic vector [17], organ specific gene-targeting
[18] and optimal regulation of therapeutic gene expression. To our
knowledge, there is no optimal vector system available which has a
regulation component dependent on disease-severity along with
heart muscle-specific gene expression [19]. Therefore, we sought
to create a heart-failure-specific gene therapy system using the B-
type natriuretic peptide (BNP) promoter [20], RNA polymerase II-
mediated short hairpin RNA (shRNA) [21] and an AAV serotype
9 (AAV9) vector [22]. As BNP expression level is reported to be a
most reliable marker of disease severity [23] in heart failure, and
its basal expression level is quite low in normal hearts and
practically negligible in other organs, BNP promoter activity may
afford control over therapeutic gene expression in both a disease-
severity-dependent- and heart-muscle-specific manner. In addi-
tion, AAV9 has the strongest avidity for heart muscle among the
serotypes [22,24]. With regard to the therapeutic target for heart
failure, we chose PP1b, the PP1 isoform of which we previously
reported that it dominantly suppresses SR-mediated Ca
2+ uptake
[25] via PLN dephosphorylation, and its expression has been
reported to be upregulated in failing hearts [26]. In the present
study, we investigated whether heart-failure-inducible inhibition of
PP1b by AAV9-mediated shRNA gene transfer is beneficial for
preventing heart failure progression in muscle LIM protein-
deficient (MLPKO) mice cardiomyopathy.
Materials and Methods
Animals
All animal protocols were approved by the Yamaguchi
University School of Medicine Animal Experiment Committee
(institutional permission # 24-014). The animals were treated
according to the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (NIH
Publication No. 85-23, revised 1996). MLPKO mice of the 129sv
strain which were obtained from the University of California San
Diego were backcrossed with C57/BL6 strain for at least 10
generations. Four-month-old MLPKO mice with a C57/BL6
background were used in the gene transfer experiments.
Preparation of adenovirus and adeno-associated virus 9
vectors for shRNA
Adenoviruses- (AdV) and AAV9s- encoding short hairpin RNA
(shRNA) were designed to obtain knockdown of mouse PP1b
mRNA in vivo for the short- and long-term, respectively. Briefly,
self-annealing oligonucleotides for PP1bshRNA and negative
control sequence (NCshRNA) were designed using a web-based
tool from Invitrogen (Carlsbad, CA), and incorporated into AdV
and AAV9 vectors harboring an expression cassette of emerald
green fluorescent protein (EmGFP) conjugated to the insertion site
of shRNA in a microRNA(miR) fragment. In AAV9 vectors, a
heart failure inducible gene expression system was employed using
the B-type natriuretic protein (BNP) promoter conjugated to
EmGFP and the miR cassette. The target sense and anti-sense
sequences (Table S1) were heated up to 94uC for 4 minutes,
gradually cooled down to 37uC for annealing, and inserted into
pcDNA6.2-GW/EmGFP-miR (Invitrogen) [27], yielding the
expression cassettes of [EmGFP-(PP1b or NC)-shRNA]. The
PP1bshRNA- and NCshRNA- expression cassettes flanked by
‘‘attB’’ and ‘‘attP’’ sequences were transferred to the entry-plasmid
(Gateway System, Invitrogen) pENTR, by incubation with BP
clonase IIH and pDONR221, yielding pENTR-6.2-GW/EmGFP-
(PP1b or NC)-shRNA plasmids. The shRNA cassettes were further
transferred from the pENTR-plasmid to AdV and AAV9 shuttle
plasmids by incubation with either LR Clonase IIH and the
pDC315-CMV-gateway plasmid, or LR Clonase IIH and the
pZAC2.1 gateway plasmid, yielding pDC315-CMV-EmGFP-
PP1bshRNA/pDC315-CMV-EmGFP-NCshRNA, or pZAC2.1-
BNP-EmGFP-PP1bshRNA/pZAC2.1-BNP-EmGFP-NCshRNA.
The successful incorporation of shRNA cassettes in the AdV and
AAV shuttle vectors was confirmed by DNA sequence analysis in
Yamaguchi University Gene Research Center. The AdV shuttle
plasmids (pDC315-based, Microbix, Toronto, Canada) were co-
transfected with the pBHGlox(delta)E1,3Cre plasmid into
HEK293 cells, followed by the purification of AdV, as previously
described [15,25]. The BNP promoter sequence [20] was
generously provided by Dr. La Pointes of the Henry Ford
Hospital, and pZAC2.1 and AAV9 construction plasmids were
kindly provided by Dr. James Wilson, the University of
Pennsylvania (UPenn). AAV9 vectors encoding the above
expression cassette were produced in the vector core facility at
Upenn [28]. The AAV9 vector expressing lacZ driven by
cytomegalovirus (CMV) promoter was also provided by Dr. James
Wilson, UPenn. For the short term analysis, AdV-CMV-EmGFP-
PP1bshRNA and AdV-CMV-EmGFP-NCshRNA were used and,
for the long term analysis, AAV9-BNP-EmGFP-PP1bshRNA and
AAV9-BNP-EmGFP-NCshRNA were utilized.
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Differentiated C2C12 cells were transfected with the AdVs at a
MOI of 20, 100 and 500, and cultured for 120 hours (h) at 37uCi n
5%CO2/95%O2 atmosphere. The total RNA of the gene
transfected hearts and C2C12 transfected with the AdVs were
prepared by using an RNAeasy kit (Qiagen, Hilden, Germany),
and the mRNA expression levels were analyzed with real-time
RT-PCR (Lightcycler 1.5,Roche). The RT-PCR primer sets for
PP1b and GAPDH described in Table S1.
Cells were lysed with an ice-cooled buffer containing (in mM) 25
Tris-HCl (pH 7.4), 1 EDTA, 1 EGTA, 50 NaCl, 1 DTT, 1
Na3VO4, 1 PMSF, 1% protease inhibitor cocktail (PIC), 1% NP-
40 and 0.5% Na-deoxycholate (RIPA buffer). Equal amounts of
the protein samples were prepared by adding an LDS buffer
(Invitrogen). Samples were heated at 70uC for 5 min, loaded on
10% bis-tris gel (NuPage, Invitrogen), electrophophoresed and
transferred to a PVDF membrane. Expression levels were
quantified by immunoblotting using PP1b specific antibodies,
followed by incubation with a secondary IgG conjugated to
horseradish peroxidase (HRP). Chemiluminescence quantification
was performed using Supersignal West Femto Substrate (Pierce,
Rockford, IL) followed by quantitative image analysis (LAS-4000,
Fuji Film, Japan).
In vivo gene transfer of AdV and AAV9
The experimental design is summarized in Figure 1. For the
short term analysis of shRNA efficiency, fourteen week-old normal
C57/BL6 mice underwent in vivo cardiac AdV delivery with direct
injection into the left ventricle (LV) (2610
9vp per site, 3sites) under
general anesthesia with 2% isoflurane, mechanical ventilation and
thoracotomy at the 3rd intercostal space, followed by closure of the
opened chest and subsequent recovery. On the 7th day after gene
transfer, LV systolic function was accessed by echocardiography,
followed by biochemical and histological analyses of the heart.
For the long term analysis of cardiac gene transfer, four-month-
old wild-type and MLPKO mice underwent AAV9 vector
injection via the tail vein (2610
11viral particles were injected per
mouse). AAV9-CMV-LacZ vector injection was used for analysis
of gene transfer efficiency in four-month-old wild type and
MLPKO mice (n=10 in each). One month after AAV9 delivery,
AAV9-CMV-LacZ treated heart was excised and transversely
sliced at a thickness of 6 mm, followed by b-gal staining, as
previously described [15].
Measurement of cell shortening and the Ca
2+ transient in
isolated mouse cardiomyocytes
One week after intramyocardial injection of AdVshRNA
vectors, mouse cardiomyocytes were enzymatically isolated to
measure the Ca
2+ transient and cell shortening. The EmGFP
expression positive cardiomyocytes were selected under fluorescent
microscopy (488 nm excitation, 510 nm emission filter) and then
used to analyze the Ca
2+ transient and cell shortening, as
previously described [9]. The % shortening of the sarcomere
and the intracellular Ca
2+ transient were simultaneously recorded
while cells were field-stimulated with 0.5 Hz. Intracellular Ca
2+
changes were expressed as changes in the fluorescence ratio
measured at 340 and 380 nm. The obtained data were analyzed
offline by IONOPTIX software (Milton, MA).
Analysis of SR protein phosphorylation
For analysis of the SR protein phosphorylation level, hearts
were homogenized with a buffer containing (in mM) 25 Tris-HCl
(pH 7.4), 50 NaCl, 300 sucrose, 1 EDTA, 1 EGTA, 50 NaF, 1
Na3VO4, 1% Nonidet P-40, 0.5% deoxycholic acid, 0.1% SDS,
0.02% 2-mercaptoethanol and 1% protease inhibitor cocktail
(PIC) (Sigma, St. Louis, MO). Protein concentrations were
calculated by the Bradford assay, followed by immunoblotting
and image analysis with LAS-4000. The phosphorylation levels of
phospholamban (PLN) at Ser16 and Thr17, the ryanodine
receptor (RyR) at Ser2808 and the cardiac troponin I (TnI) at
Ser22 and 23 were normalized to the total protein levels.
BNP promoter activity assay
The AAV9 shuttle vector plasmid (pZAC2.1-BNP-EmGFP-
PP1bshRNA) was transfected into HL-1 cells (generously provided
by Dr. W.C. Claycomb, Louisiana State University) using
lipofectamine LTX (Invitrogen). Forty eight hours after transfec-
tion, cells were stimulated with increasing doses of phenylephrine
(2, 5, and 10610
24 M) for 3 days, followed by cell lysis and
quantification of BNP mRNA with real time RT-PCR using a
primer set of mouse BNP (Table S1) or by the immunoblotting
protein expression levels of EmGFP, which represents the BNP
promoter activity of the AAV shuttle vector plasmid. The AAV9-
vector-transfected hearts were frozen in plastic containers using
isopentane precooled with liquid N2 and stored at 280uC for
further sectioning. Hearts were sectioned at a thickness of 6 mm,
fixed with 2% paraformaldehyde in phosphate buffered saline, and
immunostained with anti-GFP antibody (ab290, Abcam, Cam-
bridge, UK), followed by chemical reaction with a VECTASTAIN
ABC kit (Vector Laboratories, Burlingame, CA) and 3,39-
diaminobenzidine (DAB).
Assessment of cardiac function
Serial echocardiographic measurements were made at 1 and 3
months after gene transfer, followed by hemodynamic measure-
ment at 3 months before termination. Briefly, the left ventricular
diameter and systolic function were serially assessed by a
ultrasound machine equipped with a 15 MHz linear probe
(HDI-5000 SonoCT, Philips, Netherlands) at 1 and 3 months
after gene transfer under general anesthesia using 1.5% isoflurane
and spontaneous ventilation.
For hemodynamic analysis, mice were anesthetized with 2%
isoflurane, mechanically ventilated, and the right carotid artery
was cannulated with a 1F Millar micro-tip catheter placed in the
left ventricle (Millar instruments, Houston, TX). Maximum and
minimum LV dP/dt and the time constant of relaxation, tau (using
the exponential function), were calculated from the LV pressure as
described [15].
Quantification of cardiac interstitial fibrosis
Heart from the basal and mid-ventricular wall were transversely
sectioned at a thickness of 6 mm and stained using Heidenhain’s
trichrome staining method (Azocarmine G, aniline blue, and
Orange G). The percentage of the area of interstitial fibrosis in the
transverse heart section was automatically calculated in computer-
scanned microscopic images using SigmaScanPro 5.0 software
(Systat Software Inc., San Jose, CA).
Antibodies
The following antibodies were obtained from commercially
available sources: the antibodies for PP1b (ab16369, ab53315),
and PLN (ab2865, clone 2D12: Abcam, Cambridge, UK);
phosphorylated-PLN at Ser16, PLN, glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (Chemicon International), phosphory-
lated-PLN at Thr17, and phoshphorylated-RyR2 at Ser2808
(Badrilla, Leeds, UK); RyR2 (clone C3–33: Sigma-Aldrich, St.
Heart Failure-Inducible Gene Therapy
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Santa Cruz, CA), cardiac troponin I (cTn-I: clone 19C7),
phospho-TnI at Ser22,23 (clone 5E6: Genetex, San Antonio,
TX), and GFP(ab290: Abcam).
Statistical analysis
Comparisons between the two groups were made with Student’s
t-test. Comparisons between repeated measurements were per-
formed with ANOVA, followed by the post hoc test (the Student-
Newman-Keuls method was used to compare the two groups
when appropriate). A value of p,0.05 was considered statistically
significant. Data are expressed as the mean 6 SEM.
Results
The design of gene transfer using AdV and AAV9 is
summarized in Figure 1. Death within 5 days after gene transfer
procedure was regarded as improper recovery and these data not
incorporated for further analysis (AdV-CMV-EmGFP-PP1bsh
RNA -treated group; n=1, AdV-CMV-EmGFP-NCshRNA -
treated group, n=1). A mouse in the AAV9-BNP-EmGFP-
NCshRNA treated group died during the observational period
(2 months after gene transfer) possibly due to worsening of heart
failure and was not incorporated into further analysis.
AdV-CMV-EmGFP-PP1bshRNA effectively inhibited PP1b
expression both in vitro and in vivo
First, the AdV-PP1bshRNA induced an approximate 70%
reduction in the mRNA level (Fig. 2A and B) and 40% reduction
in the protein expression level (Fig. 2C) at a MOI of 500 in C2C12
cells compared with that of AdV-NCshRNA. Seven days after
gene transfer into the in vivo mouse hearts, approximately 40% of
the transverse myocardium exhibited GFP-positive immunostain-
Figure 1. Experimental designs. A: The experiment confirming the effect of in vivo RNA polymerase II promoter-mediated shRNA in normal mice
using AdV vectors. B: The experiment confirming AAV9-BNP promoter-mediated gene transfer transfection efficiency at 1 month after gene transfer
in normal and MLPKO mice. C: The experiment assessing the effects of in vivo AAV9-BNP promoter-mediated heart-failure condition-specific shRNA in
MLPKO mice cardiomyopathy.
doi:10.1371/journal.pone.0035875.g001
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positive myocardial area, probably due to immune reaction
against adenoviral vector [29]. In the AdV-CMV-EmGFP-
PP1bshRNA injected group, the expression level of the PP1b
protein was reduced by 30% compared to that of control vectors
(Fig. 2E).
AdV-PP1bshRNA resulted in enhanced SR Ca
2+ cycling
and increased PLN phosphorylation
As shown in the representative tracing of Figure 3A, the AdV-
PP1bshRNA treated cardiomyocytes exhibited marked enhance-
ment in the transient Ca
2+ level and % shortening of the
sarcomere length (%SS). There were significant increases in the
%SS, maximum/minimum first derivative of sarcomere length
Figure 2. In vivo and in vitro adenoviral mediated PP1bshRNA significantly reduced expression of PP1b in C2C12 cells and mice
hearts. A: Vector structure of the adenoviral-PP1bshRNA under the control of the CMV promoter and marker gene expression of EmGFP. The
negative control sequence of miR was used as a shRNA control sequence (NCshRNA). B and C: Efficiency of AdV-CMV-EmGFP-PP1bshRNA assessed by
real-time RT-PCR (left panel) and immunoblotting of PP1b (right panel) at increasing MOIs of transfections 5 days after adenoviral infection in
differentiated C2C12 cells. D: Immunostaining of GFP in the transverse heart section at 7 days after direct adenoviral injection, showing the
representative transfection efficiency. The lower panel shows the site of local inflammation (indicated by arrows) 7 days after adenoviral gene
transfer. E: Immunoblotting of PP1b from LV homogenates and a summary of quantitative image analysis normalized by the amount of GAPDH
expression. ‘‘*’’ indicates p,0.05 vs. control. (n=8 in the PP1bshRNA group, n=8 in the NCshRNA group).
doi:10.1371/journal.pone.0035875.g002
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decay slope (Tau) and amplitude of the Ca
2+ transient compared
to those of the control vector (Fig. 3B). In heart homogenates, the
phosphorylation level of PLN at Ser16 in the PP1bshRNA treated
hearts was significantly enhanced compared with those receiving
NCshRNA treatment (Fig. 3C). On the other hand, there were no
significant changes in the phosphorylation levels of the RyR at
Ser2808. Moreover, there were no significant changes in the
phosphorylation levels of either PLN at Ser17 or cardiac troponin
I at Ser22/Ser23. Furthermore, the protein expression levels of
SERCA2a, PP1a and PP1c was not significantly altered in these
two groups (Fig. S1).
A partial reduction of PP1b is sufficient to enhance LV
contractility in the normal mouse heart
One week after adenoviral injection, LV systolic function in the
AdV-PP1bshRNA-treated heart showed a significant increase in
LV fractional shortening (%FS) without changes in LV end-
diastolic diameter or heart rate. These data indicate that a partial
reduction of PP1b by PP1bshRNA is sufficient to enhance cardiac
contractility by augmenting SR Ca
2+ cycling in normal mice
(Table S2).
AAV9- mediated inducible PP1bshRNA was only
activated in the cardiomyopathic hearts and partially
reduced the PP1b expression level
Because adenoviral gene transfer showed local inflammatory
response (Fig. 2D) and the duration of transgene expression is
limited for short term, we switched the gene transfer vector system
from AdV to AAV9 for long-term analysis [29]. Namely, we tested
whether the AAV9 vector exhibits heart-failure inducible
PP1bshRNA in genetic mouse cardiomyopathy (MLPKO mice)
(Fig. 1B and C, Fig. 4A).
Induction of the BNP promoter-mediated EmGFP expression
and PP1bshRNA were initially tested in vitro in a mouse cardiac
cell line (HL-1) with increasing doses of an a-adrenergic stimulant,
phenylephrine (PE). As shown in the left panel of Figure 4B, PE
significantly increased mouse BNP mRNA in a dose-dependent
manner. Similarly, the EmGFP protein expression driven by the
human BNP promoter in the AAV9 vector was also significantly
augmented in a PE-dose-dependent manner (Fig. 4B right panel).
The EmGFP expression level with the BNP promoter was
approximately one-third compared with that of the CMV
promoter in in vitro HL-1 cells with 500 mM phenylephrine
(Fig. 4C).
Single tail vein injection of the AAV9 vector (2610
11 vp)
expressing lacZ with the CMV promoter yielded more than 80%
positive b-gal-staining myocardium in transverse heart sections
(n=10) from the MLPKO mice at 1 month, confirming the
relatively higher infectivity of AAV9 in the heart compared to the
other organs (Fig. 4D left panel, Fig. 4F left panels), as previously
described [30]. Next, the same amount of the AAV9 (2610
11 vp)
expressing EmGFP-NCshRNA was injected through the tail vein.
One month after gene transfer, a robust expression of EmGFP
throughout the transverse heart section was detected in the
MLPKO cardiomyopathic heart (Fig. 4D middle), whereas no
significant EmGFP expression was detected in the wild type heart
(Fig. 4D, right panels).
Furthermore, AAV9-BNP-EmGFP-NCshRNA treated MLP
KO mice did not show any EmGFP expression in other organs,
including the skeletal muscle, kidney, liver, pancreas, spleen, and
lung (Fig. 4F), whereas the AAV-CMV-lacZ treated mice showed
trace expression of b-gal positive staining in the skeletal muscle,
kidney, and pancreas.
Consequently, PP1bprotein expression was reduced by approx-
imately 25% at 3 months after gene transfer in AAV9-BNP-
EmGFP-PP1bshRNA infected MLPKO heart homogenates
compared with that of AAV9-EmGFP-NCshRNA treated hearts
(n=8 in each group). Interestingly, the relative amount of PP1b
reduction was somewhat similar to the amount of the increase in
PP1b expression in the untreated MLPKO hearts compared with
that of wild-type mice (Fig. S2).
These data indicate that BNP promoter-driven EmGFP
expression is predominantly regulated only in the failing heart,
not the normal heart, thereby contributing to the suppression of
PP1b protein expression in the failing hearts. Indeed, in MLPKO
mice of the same age, there was a dramatic increase in mouse BNP
mRNA in the MLPKO mouse heart compared with the wild type
(Fig. S3), supporting the notion that PP1bshRNA was only
activated in the failing MLPKO hearts.
AAV9-BNP-promoter-mediated PP1b shRNA significantly
improved LV systolic and diastolic function in MLP KO
mice
At the time of AAV9 injection, MLPKO mice exhibited a
marked reduction in the % fractional shortening (%FS) of the LV,
as well as dilated LV end-diastolic and end-systolic diameter
(LVDd and LVDs, respectively), thinner LV posterior wall
thickness (LVPWs), and increased wall stress index (LVDd/
LVPWT), compared with that of their wild-type littermates
(Fig. 5A and B). The AAV9-BNP-EmGFP-PP1bshRNA treated
group exhibited significantly improved %FS, reduced LVDd, and
inhibited thinning of LVPWs at 3 months after gene transfer
compared with the AAV9-BNP-NCshRNA treated group (Fig. 5A
and B). Furthermore, the wall stress index was significantly
ameliorated throughout the experimental period in the
PP1bshRNA treated group compared with the NCshRNA treated
group (Fig. 5B).
As shown in Figure 5C, the PP1bshRNA-treated mice exhibited
a dramatically improved LV pressure tracing pattern; namely, the
elevated LV end-diastolic pressure was mitigated, and the first
derivative curve of LV pressure during diastole exhibited a sharp
and convex shape, whereas that of the NCshRNA treated mice
exhibited a dull and concave shape (Fig. 5C). As summarized in
Figure 5D, AAV9-BNP-PP1bshRNA significantly improved
minimum (negative) LV dP/dt and Tau (the time constant of
isovolumic LV pressure fitted by exponential function) compared
with the AAV9-NCshRNA treated hearts. There was also a
tendency of improved maximum (positive) dP/dt in the AAV9-
BNP-PP1bshRNA treated MLPKO hearts, but it did not attain
statistical significance. These data indicate that AAV9-BNP
mediated PP1bshRNA mainly ameliorated LV diastolic function
and helped prevent adverse left ventricular remodeling in MLP
KO mice throughout the experimental period.
AAV9-BNP-PP1bshRNA mediated changes in biochemical
parameters
In the heart homogenates, the phosphorylation levels of PLN at
Ser16 in the AAV9-BNP-EmGFP-PP1bshRNA treated hearts was
significantly increased compared with the NCshRNA treated one
(Fig. 6A). As similarly observed in the AdV transfection
experiment, there were no changes in the phosphorylation levels
of the RyR at Ser2808, and no changes in the expression levels of
PLN or RyR (Fig. 6 A and B).
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2+ transient and % sarcomere shortening in AdV-PP1bshRNA
mice cardiomyocytes. Cardiomyocytes were isolated from the mouse hearts 7 days after gene transfer, followed by an analysis of sarcomere
shortening and the Ca
2+ transient using the Ionoptix system with fura-2 AM dye. Sarcomere length was calculated in a real-time manner using the
SarcLen software of the Ionoptix system. A: Representative tracing of sarcomere shortening and Ca
2+ transient in enzymatically isolated
cardiomyocytes from the mouse heart 7 days after adenoviral transfection. B: Summaries of the analysis in sarcomere shortening and Ca
2+ transients;
namely, % sarcomere shortening (%SS), the maximum/minimum value of the first derivatives of sarcomere length (+dL/dt, 2dL/dt, respectively), the
time constant of the Ca
2+ transient decay slope (Ca
2+ transient Tau), and the amplitude of the Ca
2+ transient (Ca
2+ transient amplitude). ‘‘*’’ indicates
p,0.01 vs. NCshRNA control group. (n=38 in the NCshRNA group, n=35 in the PP1bshRNA group). C: Immunoblots of the key SR phosphoproteins
and the phospholylation levels 7 days after gene transfer. Note that the phosphorylation levels of PLN at Ser16 was augmented in the PP1bshRNA
treated group compared with that of the NCshRNA treated group. D: Summaries of the phospholylation levels of PLN at Ser16 and RyR at 2808 in
each group. ‘‘*’’ indicates p,0.05 vs. the NCshRNA treated group. (n=6 in the NCshRNA group, n=6 in the PP1bshRNA group).
doi:10.1371/journal.pone.0035875.g003
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35875Figure 4. AAV9- mediated heart-failure-inducible PP1bshRNA and partial reduction in PP1b expression. A: Vector structure of the
adeno-associated virus 9 (AAV9) -PP1bshRNA flanked by 39 and 59 inverted terminal repeats (ITR) under the control of the brain natriuretic peptide
(BNP) promoter and marker gene expressison of EmGFP. The negative control sequence of miR was used as a shRNA control sequence (NCshRNA).
AAV9 vector expressing lacZ driven by the CMV promoter was used to assess the in vivo transfection efficiency through the tail vein injection of AAV9
gene transfer into the heart. B: The expression levels of BNP mRNA and EmGFP protein were dose-dependently increased with phenyrephrine (PE) in
the pZAC2.1-BNP-EmGFP-PP1bshRNA (AAV9 vector plasmid) transfected HL-1 cells. ‘‘*’’ indicates p,0.001 vs PE(2),‘‘#’’ indicates p,0.001 vs PE
1610
24 M, ‘‘**’’ indicates p,0.05 vs PE 2610
24 M, ‘‘##’’ indicates p,0.01 vs PE 2610
24 M, ‘‘{’’ p,0.05 vs PE(2),‘‘{{’’ p,0.05 vs PE 2610
24 M.
(nBNP; normalized BNP expression, nGFP; normalized EmGFP expression). C: Comparison of EmGFP expression levels with BNP- versus CMV-
promoter. The normalized EmGFP expression levels were estimated 48 hours after plasmid transfection of pDC316-CMV-EmGFP-PP1bshRNA and
pZAC2.1-BNP- EmGFP-PP1bshRNA in HL-cells. ‘‘*’’ indicates p,0.01 vs the CMV promoter treated group. D: Bluo-gal staining of transverse heart
sections at the papillary muscle level in AAV9-CMV-LacZ transfected MLPKO mice (left panel), and immunostaining of EmGFP proteins in the AAV9-
BNP-PP1bshRNA transfected hearts in MLP knockout mice(middle panel) and wild type mice (right panel). The expression level of EmGFP was clearly
detected by an anti-GFP antibody (Abcam) as a brown color in the GFP-immunostaining indicates positive cardiomyocytes. The scale bar indicates
50 mm. E: Immunoblotting of PP1b in LV homogenates from the transfected MLP knockout hearts with AAV9-BNP-EmGFP-PP1bshRNA and AAV9-
BNP-EmGFP-NCshRNA. The graph under the immunoblot indicates quantitative analysis of PP1b expression normalized by GAPDH. PP1b expression
levels were decreased by 25% in the PP1bshRNA treated group. ‘‘*’’ indicates p,0.05 vs. NCshRNA treated group. (n=8 in each group). F: Bluo-gal
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PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e35875Moreover, the AAV9-BNP-PP1bshRNA-treated hearts signifi-
cantly reduced mouse BNP mRNA expression compared with the
AAV9-BNP-NCshRNA treated hearts (Fig. 6C). Cardiac intersti-
tial fibrosis was significantly reduced by BNP-PP1bshRNA
compared with NCshRNA. There was no significant changes in
the expression levels of the other PP1 isoforms, SERCA2a, or
cardiac troponin I (Fig. S4).
Discussion
In the present study, we demonstrated that AdV vector-
mediated PP1bshRNA treatment dramatically augmented SR
Ca
2+ cycling in normal mice cardiomyocytes. Furthermore, AAV9
vector-mediated heart failure-inducible PP1bshRNA treatment
prominently improved LV diastolic function, and mitigated
progressive left ventricular remodeling in MLPKO mice, an
animal model which mimics human dilated cardiomyopathy. In
addition, there was a significant reduction in BNP production and
cardiac interstitial fibrosis, both of which seem to be coincident
with ameliorated cardiac function. To our knowledge, this is the
first experimental study that reports a heart-tissue-specific and
heart-failure-condition-specific gene therapy for the treatment of
heart failure.
The effect of PP1bshRNA on the improved in vivo LV function
is attributed to increased PLN phosphorylation at Ser16 in the
cardiomyopathic hearts. In the previous in vitro experimental study,
we demonstrated that PP1b was the most significantly involved
isoform among the three PP1 catalytic subunits in regulating SR
Ca
2+ uptake. Furthermore, PP1b was found to preferentially
interact with the SERCA2a and PLN protein complexes in the
longitudinal SR, thereby suppressing SR-mediated Ca
2+ cycling in
cardiomyocytes. As PP1b protein expression has been shown to be
upregulated in human heart failure and animal models of
cardiomyopathy, shRNA-mediated suppression of PP1b appears
to be a promising approach to restore impaired SR Ca
2+ cycling in
the failing heart. Indeed, PP1b expression in failing MLPKO
hearts was upregulated by approximately 30% (Fig. S2). BNP
promoter driven PP1bshRNA suppressed PP1b expression by
approximately 25%, which was similar to the levels of increase in
PP1b in the failing myocardium. Thus, this unique gene transfer
approach convincingly demonstrates that heart-failure-condition-
specific suppression of PP1b is sufficient to improve cardiac
function for 3 months in MLPKO cardiomyopathy. In addition, as
PP1b is a ubiquitously distributed serine/threonine phosphatase,
both the heart-specific and heart-failure specific gene regulation
was essential to prevent systemic side effects.
We and others have previously reported that increased PP1
activity was a exacerbating factor in animal models of heart failure
[15] as well as human heart failure [31] and that PP1 inhibition by
the overexpression of endogenous inhibitors was beneficial to
preventing heart failure progression using either viral vector
mediated gene transfer study or a transgenic mouse approach
[14,16]. For example, Pathak et al. [32] reported that a constitutive
form of INH-1c-overexpressing mouse hearts displayed a hypercon-
tractile phenotype in chronic-pressure-overload- and chronic-
isoproterenol-infusion- heart failure models, resulting in rescued
heart failure progression. We also reported that AAV2-mediated
gene delivery of INH-2 prevented the progression of hamster
cardiomyopathy [15]. In contrast, El-Armouche and colleagues [33]
reported that INH-1 knockout mice were protected from isoproter-
enol-induced cathecolamine injury, whereas INH-1c overexpression
[34] resulted in cardiomyomyopathy and susceptibility to lethal
arrhythmia. Grote-Wessels et al. [35] reported that heart-specific
transgenic overexpression of a constitutively active form of INH-2
failed to rescue pressure overload-induced mice cardiomyopathy. In
this regard, our PP1bshRNA approach may attract similar criticism.
However, as discussed inthe recent reviews byWittkopper at al [36],
the extent of the PP1 inhibition by a PP1 endogenous inhibitor or
PP1bshRNAmight be essential todeterminewhether PP1 inhibition
can improve cardiac dysfunction without adverse complications.
Our heart failure inducible system worked only during the
exacerbation of heart failure, suggesting that appropriate regulation
in PP1 activity was critical for the therapeutic activity of cardiac SR-
mediated Ca
2+ upregulation. Although we could not determine
whether PP1bshRNA can extend the survival time in MLPKO
cardiomyopathic mice, ameliorated cardiac BNP production and
interstitial fibrosis may be associated with better outcome. Further
study investigating the survival of the animals is clearly needed. In
this regard, it should be tested in the other animal model which
manifests clinically relevant features of human heart failure.
From the clinical viewpoint, a cardiac gene therapy clinical trial
using intracoronary catheter delivery of AAV1 expressing
SERCA2a is already underway to test the beneficial effect of
SERCA2a supplementation in patients with severe heart failure
[37]. The phase 2 study results were very promising [11], but a
potential drawback is that it may not be possible to control the
gene expression when it no longer be needed. A BNP promoter-
driven approach may provide a solution to the critical need for an
on/off switch in gene expression, as the healthy heart does not
produce BNP.
On the other hand, it is important to be aware of the fact that
chronic inotropic therapy is contraindicated for treating patients
with chronic heart failure, as earlier clinical trial using milrinone
failed to rescue patients, and in fact turned out to cause an adverse
outcome in the 1980’s [38]. One plausible mechanism for the
deleterious effect of this phosphodiesterase III inhibitor was that it
was associated with chronic augmentation of intracellular cyclic
AMP, and subsequent overactivation of protein kinase A, in the
failing hearts [39]. This is unlikely in the PP1 inhibition study,
because PP1 inhibition in cardiomyocytes does not increase
intracellular cyclic AMP or activate protein kinase A [15]. In this
regard, we often face a situation that we have to use an inotropic
agent to improve hemodynamic status in patients with acutely
exacerbated chronic heart failure. This BNP guided regulatory
gene therapy approach targeting PP1b may offer a new strategy
that maintains the hemodynamic status only when cardiac
function has become acutely exacerbated and there is increased
BNP promoter activity in the failing heart.
Regarding the role of AAV serotype 9, it has been reported to
be very effective for cardiac gene transfer [22] and stable transgene
expression was shown to last more than 1 year in rats. As a higher
dose AAV injection has been reported to cause T-cell activation
[17], a less immunogenic vector delivery system is required. In this
regard, the receptor that recognizes AAV9 was recently deter-
mined to be cell surface b-galactose [28], and its transfection
efficiency is potentially further modifiable by administrating drugs.
staining of AAV-CMV-LacZ injected mice organs (left column) and immunostaining of GFP inAAV9-EmGFP-PP1bshRNA. There were no detectable
levels of the GFP shRNA vector in organs other than the heart, whereas the AAV9-CMV-lacZ vector exhibited a trace expression of lacZ in skeletal
muscle, kidney and pancreas. There was no detectable expression in liver, spleen and lung. The scale bar indicates either 50 mm or 100 mm, as
indicated in each panel.
doi:10.1371/journal.pone.0035875.g004
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PLoS ONE | www.plosone.org 10 April 2012 | Volume 7 | Issue 4 | e35875Figure 5. AAV9-mediated heart-failure-inducible PP1bshRNA improved systolic and diastolic function and inhibited LV remodeling.
A: Representative M-mode echocardiographic tracings 12 weeks after AAV9-BNP-PP1bshRNA treated MLP knockout mice compared with that of
AAV9-BNP-NCshRNA treated mice. B: Serial cardiac function evaluated by echocardiogram after gene transfer. ‘‘*’’ indicates p,0.05 vs the NC group
post GT after 12 weeks. ‘‘#’’ indicates p,0.05 vs. an age-matched wild type mouse. C: Representative tracing of LV pressure and dP/dt in the
PP1bshRNA and NCshRNA treated groups. The scale bar indicates 200 msec. D: Summaries of the hemodynamic data analysis. ‘‘*’’ indicates p,0.05
vs. the NCshRNA treated group, (n=7 in the PP1bshRNA treated group, n=6 in NCshRNA treated group.).
doi:10.1371/journal.pone.0035875.g005
Figure 6. AAV9-mediated heart-failure-inducible PP1bshRNA increased PLN phosphorylation at Ser16, reduced BNP expression,
and ameliorated cardiac interstitial fibrosis. A: Immunoblots of the key SR phosphoproteins and analysis of the phosphorylation levels by
using phosphospecific antibodies in LV homogenates at 3 months after gene transfer. B: Summaries of the phospholylation levels of PLN at Ser16
and RyR at Ser2808. ‘‘*’’ indicates p,0.05 vs. the NCshRNA treated group. (n=8 in PP1bshRNA treated group and n=8 in NCshRNA treated group). C:
Expression analysis of normalized BNP (nBNP) using real-time RT-PCR from the AAV9 shRNA transfected heart tissue. ‘‘*’’ indicates p,0.05 vs. the
NCshRNA treated group. (n=8 in the NCshRNA treated group, n=8 in the PP1bshRNA treated group). D: Representative images of Heidenhain’s
trichrome staining in the AAV9-BNP-EmGFP-NCshRNA- andAAV9-BNP-EmGFP-PP1bshRNA treated hearts at 3 months after gene transfer. The lower
graph shows the quantitative image analysis of percentage of the area of interstitial fibrosis. ‘‘*’’ indicates p,0.05 vs. the NCshRNA treated group.
(n=6 in NCshRNA treated group and n=7 in PP1bshRNA treated group).
doi:10.1371/journal.pone.0035875.g006
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PLoS ONE | www.plosone.org 11 April 2012 | Volume 7 | Issue 4 | e35875Therefore, AAV9 might be a good choice as a vector in
combination with heart failure-specific gene regulation for the
treatment of severe heart failure in order to minimize any adverse
immune response. Further study will be required to establish the
optimal clinically relevant gene transfer vector system.
In summary, we performed AAV9-mediated heart-failure
condition specific in vivo knockdown of PP1b, which is the PP1
isoform harboring the greatest impact on cardiomyocye SR Ca
2+
uptake via PLN phospholylation, resulting in improved cardiac
function and prevention of adverse LV remodeling in the failing
heart. Future study using other heart failure animal models,
including large animals, is warranted.
Supporting Information
Figure S1 Immunoblottings of cardiac troponin I, SERCA2a,
and PP1 catalytic subunit a and c in LV homegenates from AdV-
transfected mice heart. LV specimens were obtained at 7 days
after direct adenoviral injection into the heart.
(TIF)
Figure S2 A: Body weight, heart weight, and heart/lung weight
ratio in 4 month-old MLP knockout mice and age-matched wild-
type littermates. B: Immunoblottings of PP1 catalytic subunit
isoforms, a, b/d, and c in LV homogenates. a-Actininn was used
as protein loading control. Left graphs indicates quantitative
immunoblot analysis of PP1 a, b/d, and c in MLP knockout mice
and age-matched wild type littermates.
(TIF)
Figure S3 BNP expression analysis by using real-time RT-PCR
in 4–5 month-old MLP knockout mice and age-matched wild type
littermate hearts. ‘‘*’’ indicates p,0.05 vs. wild type littermates.
(TIF)
Figure S4 Immunoblottings of cardiac troponin I, SERCA2a,
and PP1 catalytic subunit a and c in LV homegenates from
AAV9-transfected mice heart. LV specimens were obtained at 3
month after tail-vein-mediated AAV9 gene transfer.
(TIF)
Table S1 Sequence information for shRNA and real-
time PCR analysis. The bold characters in the mouse
PP1bshRNA and mouse NCshRNA indicate 59-overhang se-
quence for the directed ligation reaction with pcDNA6.2-GW/
EmGFP-miR plasmid.
(DOC)
Table S2 Serial echocardiogram data after AdV vector
injection. Abbreviations in the table are as follows; GT: gene
transfer, %FS: % fractional shortening of the left ventricle, LVDd:
left ventricular end-diastolic dimension, LVDs: left ventricular
end-systolic dimension, LVPWs: left ventricular posterior wall
thickness at systole. ‘‘*’’ indicates p,0.01 vs. NC-shRNA group
(Post GT), n=14 in each group.
(DOC)
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